MedTrace Logo

Long-Term Follow-Up Safety Monitoring of Patients Dosed in the First-in-Man Phase I/II Study of TT-034.

NCT02315638 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 9

Last updated 2018-09-26

No results posted yet for this study

Summary

This is a long-term safety follow-up protocol for subjects who received TT-034 under the B2801001 protocol and consists of monitoring for at least 4.5 years.

Conditions

  • Hepatitis C

Sponsors & Collaborators

  • Tacere Therapeutics, Inc.

    lead INDUSTRY

Principal Investigators

  • David Suhy, PhD · Tacere Therapeutics, Inc.

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-11-30
Primary Completion
2018-09-24
Completion
2018-09-24

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02315638 on ClinicalTrials.gov